Tom Powles: Enfortumab vedotin and Pembrolizumab improving PFS and OS by 55% and 53% respectively compared to platinum based chemo in 1st line UC (+avelumab in 30%)
Tom Powles, Director of Barts Cancer Centre, shared on Twitter:
“Enfortumab vedotin and Pembrolizumab improving PFS and OS by 55% and 53% respectively compared to platinum based chemo in 1st line UC (+avelumab in 30%). Chemo has not been beaten before (despite multiple efforts). RR and CR of 68% & 29% is hard to beat. DOR not reached.
Tox was in line with expectations. Grade 3-5 TRAEs in 56% vs 70% for EVP and chemo respectively. 21% of EVP patients discontinuing for adverse events. G3+ skin tox and peripheral neuropathy occurred in 8% and 4% with no Grade 5. EVP tox is different from chemo but not worse.
Overall EVP looks transformative, superseding chemo/IO approaches. It’s attractive for patients and will hopefully get approved for use in the near future. Huge thanks to the research team and the patients.”
Source: Tom Powles/Twitter
-
Dec 8, 2023, 17:10 | OpinionAaron Goodman: Let’s stop giving many cured young patients neuropathy
-
Dec 8, 2023, 16:29 | BlogBecome a SIOP member today or renew for 2024 membership year - SIOP
-
Dec 8, 2023, 15:51 | BlogSharon Kapambwe: Standing on the shoulders of giants- Professor Lynnette Denny
-
Dec 8, 2023, 12:47 | InsightTalha Badar: A few selected ALL abstracts to watch for at ASH23
-
Dec 9, 2023, 04:44President Biden: It's good for the millions of Americans who can't afford their medications
-
Dec 8, 2023, 17:40Ibrahim Halil Sahin: A common question I received after my tweet on the PEGASUS trial...
-
Dec 8, 2023, 17:32Daniel Stover: Tumor genomic testing (TGT) is standard for MBC patients
-
Dec 8, 2023, 12:47Talha Badar: A few selected ALL abstracts to watch for at ASH23
-
Dec 8, 2023, 12:40Amar Kelkar: We hope putting out independent cost-effectiveness analyses like this will encourage others to join
-
Dec 8, 2023, 16:33Big thank you to Dr. Rucha Kiran Patil for sharing their experiences and learnings on writing abstracts and poster presentations - Novo Nordisk Haemophilia Foundation
-
Dec 6, 2023, 14:57Tracy Gosselin: Jennifer Petruno Receives DAISY Award for Extraordinary Nurses
-
Dec 3, 2023, 16:34Tedros Adhanom Ghebreyesus: Grateful to Namibia’s Prime Minister Saara Kuugongelwa-Amadhila for her commitment to health
-
Dec 2, 2023, 18:08100 Influential Celebrities in Oncology: The 2023 Edition – Part 5
-
Dec 2, 2023, 16:50Mara Antonoff: When your famous friends come back to visit their humble beginnings
-
Dec 4, 2023, 16:26SIOP 2023 by Numbers! - International Society of Paediatric Oncology
-
Dec 2, 2023, 16:43In our recent survey, nearly 1,700 ASCO members shared feedback on the ABIM MOC requirements - ASCO
-
Nov 28, 2023, 17:34The International Association of Cancer Registries annual conference - IARC
-
Nov 26, 2023, 18:05Submit your abstract by 13 February for ESMO-Breast-24 - ESMO
-
Nov 26, 2023, 17:58Lisa A. Lacasse: My sincere gratitude to the ACS CAN team, our incredible volunteers, and supporters for another outstanding year
-
Dec 8, 2023, 17:54Dana-Farber News congratulates Sara Tolaney on receiving the Susan G. Komen 2023 Rising Star Researcher Award
-
Dec 8, 2023, 17:35Timothy M. Pawlik: Excited to announce Samilia Obeng-Gyasi as THE inaugural Endowed Surgical Professor in Health Equity
-
Dec 7, 2023, 18:30Dinesh Pendharkar is appointed as an Adjunct Professor at Roswell Park Comprehensive Cancer Center
-
Dec 7, 2023, 04:37Karun Neupane: Dreams do come true. I am going to Moffitt Cancer Center to become a hematologist/oncologist!
-
Dec 6, 2023, 16:21Sandra L. Wong has been appointed the next Dean of Emory University School of Medicine and chief academic officer for Emory Healthcare - Emory School of Medicine